RecruitingNCT06800768
The Value of 68Ga-FAPI PET/CT in Detecting Recurrent and Metastatic Lesions in Patients with Thyroid Cancer After Surgery
Sponsor
Ruijin Hospital
Enrollment
40 participants
Start Date
Feb 1, 2025
Study Type
OBSERVATIONAL
Conditions
Summary
This study aims to investigate the value of 68Ga-FAPI PET/CT in detecting recurrent and metastatic lesions in patients with thyroid cancer after surgery.
Eligibility
Min Age: 18 YearsMax Age: 80 Years
Plain Language Summary
Simplified for easier understanding
This study is evaluating a new type of PET/CT scan using a tracer called 68Ga-FAPI to see if it's better at detecting cancer recurrence or spread in thyroid cancer patients who have already had surgery.
**You may be eligible if...**
- You have had surgery for thyroid cancer
- There is clinical suspicion that your cancer may have come back or spread
- You are between 18 and 80 years old
- You can follow the study procedures
**You may NOT be eligible if...**
- You have severe heart or lung problems
- You have serious bone marrow, liver, or kidney dysfunction
- You have a bowel obstruction or difficulty swallowing
- You are pregnant or breastfeeding
Talk to your doctor to see if this trial is right for you.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06800768
Related Trials
Studies on Tumors of the Thyroid
NCT000011601 location
DESTINY-PANTUMOUR04
NCT0712400017 locations
A Study to Collect Information About the Use of Redifferentiating Medications as a Standard Treatment for Thyroid Cancer
NCT057330131 location
A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors
NCT0553813077 locations
Zanzalintinib for the Treatment of Advanced Thyroid Cancer Before Surgery
NCT069595111 location